NASDAQ:TROVTrovaGene Stock Price, Forecast & News

$3.21

-0.19 (-5.59 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$3.06

Now: $3.21▼

$3.40

50-Day Range

$0.90

MA: $1.44▼

$3.31

52-Week Range

$0.70

Now: $3.21▼

$3.46

Volume420,611 shs

Average Volume648,892 shs

Market Capitalization$35.35 million

P/E RatioN/A

Dividend YieldN/A

Beta1.04

Trovagene, Inc., a clinical-stage, precision medicine oncology therapeutics company, develops oncology therapeutics for cancer care by leveraging its proprietary Precision Cancer Monitoring (PCM) technology in tumor genomics. Its lead drug candidate, PCM-075, is a Polo-like Kinase 1 selective adenosine triphosphate competitive inhibitor. The PCM-075 is in Phase Ib/II clinical trial in acute myeloid leukemia (AML) and has completed a Phase I clinical trial in advanced solid tumors. The PCM-075 is also in preclinical studies with approximately 10 chemotherapeutic and target agents used in hematologic and solid tumor cancers, including Zytiga (abiraterone acetate); Beleodaq (belinostat); Quizartinib (AC220), a development stage FLT3 inhibitor; and Velcade (bortezomib) in AML, metastatic castration-resistant prostate cancer and other hematologic and solid tumor cancers. Trovagene, Inc. primarily serves pharmaceutical companies and third party laboratories. The company was formerly known as Xenomics, Inc. and changed its name to Trovagene, Inc. in January 2010. Trovagene, Inc. was founded in 1999 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
TrovaGene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.50, TrovaGene has a potential upside of 351.7% from its current price of $3.21.
Amount of Analyst Coverage
TrovaGene has received no research coverage in the past 90 days.

2.9 Community Rank

Outperform Votes
TrovaGene has received 402 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
TrovaGene has received 296 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
TrovaGene has received 57.59% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about TrovaGene and other stocks. Vote “Outperform” if you believe TROV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe TROV will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
TrovaGene does not currently pay a dividend.
Dividend Growth
TrovaGene does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, TrovaGene insiders have bought more of their company's stock than they have sold. Specifically, they have bought $600,000.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 0.60% of the stock of TrovaGene is held by insiders.
Percentage Held by Institutions
Only 9.99% of the stock of TrovaGene is held by institutions.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of TrovaGene is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of TrovaGene is -1.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
TrovaGene has a P/B Ratio of 3.41. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.88 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Biological products, except diagnostic

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:TROV

Previous Symbol

CUSIPN/A

CIK1213037

Webwww.trovagene.com

Phone858-952-7570

Debt

Debt-to-Equity Ratio0.12

Current Ratio2.37

Quick Ratio2.37

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$250,000.00

Price / Sales141.38

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.94 per share

Price / Book3.41

Profitability

EPS (Most Recent Fiscal Year)($2.80)

Net Income$-16,410,000.00

Net Margins-3,688.31%

Return on Equity-202.00%

Return on Assets-122.92%

Miscellaneous

EmployeesN/A

Outstanding Shares11,011,000

Market Cap$35.35 million

Next Earnings Date8/6/2020 (Estimated)

OptionableOptionable

Receive TROV News and Ratings via Email

Sign-up to receive the latest news and ratings for TROV and its competitors with MarketBeat's FREE daily newsletter.

TrovaGene (NASDAQ:TROV) Frequently Asked Questions

How has TrovaGene's stock been impacted by COVID-19 (Coronavirus)?

TrovaGene's stock was trading at $1.11 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, TROV stock has increased by 189.2% and is now trading at $3.21. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of TrovaGene?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for TrovaGene in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for TrovaGene.

When is TrovaGene's next earnings date?

TrovaGene is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for TrovaGene.

How were TrovaGene's earnings last quarter?

TrovaGene Inc (NASDAQ:TROV) announced its quarterly earnings results on Thursday, February, 27th. The medical research company reported ($0.51) earnings per share for the quarter, beating the consensus estimate of ($0.65) by $0.14. The medical research company had revenue of $0.09 million for the quarter. TrovaGene had a negative net margin of 3,688.31% and a negative return on equity of 202.00%. View TrovaGene's earnings history.

When did TrovaGene's stock split? How did TrovaGene's stock split work?

TrovaGene's stock reverse split on Wednesday, February 20th 2019. The 1-6 reverse split was announced on Tuesday, February 19th 2019. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 19th 2019. An investor that had 100 shares of TrovaGene stock prior to the reverse split would have 17 shares after the split.

What price target have analysts set for TROV?

2 analysts have issued 1 year price targets for TrovaGene's stock. Their forecasts range from $6.00 to $23.00. On average, they anticipate TrovaGene's stock price to reach $14.50 in the next year. This suggests a possible upside of 351.7% from the stock's current price. View analysts' price targets for TrovaGene.

What are Wall Street analysts saying about TrovaGene stock?

Here are some recent quotes from research analysts about TrovaGene stock:

1. According to Zacks Investment Research, "Trovagene is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene has intellectual property and proprietary technology that enables the Company to analyze circulating tumor DNA (ctDNA) and clinically actionable markers to identify patients most likely to respond to specific cancer therapies. Trovagene plans to continue to vertically integrate its tumor genomics technology with the development of targeted cancer therapeutics. " (3/21/2020)
2. Maxim Group analysts commented, "Trovagene reported 2Q19 with a net loss of ($4.1M) and ended the period with $10.8M in cash on the balance sheet." (8/9/2019)

Has TrovaGene been receiving favorable news coverage?

Media coverage about TROV stock has trended positive on Saturday, InfoTrie reports. The research firm identifies negative and positive press coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. TrovaGene earned a daily sentiment score of 3.0 on InfoTrie's scale. They also assigned media coverage about the medical research company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutTrovaGene.

Who are some of TrovaGene's key competitors?

Some companies that are related to TrovaGene include Cidara Therapeutics (CDTX), X4 Pharmaceuticals (XFOR), La Jolla Pharmaceutical (LJPC), Solid Biosciences (SLDB), Applied Genetic Technologies (AGTC), Surface Oncology (SURF), BIONDVAX PHARMA/S (BVXV), Gamida Cell (GMDA), Outlook Therapeutics (OTLK), Champions Oncology (CSBR), Windtree Therapeutics (WINT), Neon Therapeutics (NTGN), Organovo (ONVO), AIM ImmunoTech (AIM) and Genocea Biosciences (GNCA). View all competitors.

What other stocks do shareholders of TrovaGene own?

Based on aggregate information from My MarketBeat watchlists, some companies that other TrovaGene investors own include XOMA (XOMA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Inovio Pharmaceuticals (INO), NVIDIA (NVDA), Zynerba Pharmaceuticals (ZYNE), Alnylam Pharmaceuticals (ALNY), Opko Health (OPK), Protalix Biotherapeutics (PLX) and Idera Pharmaceuticals (IDRA).

Who are TrovaGene's key executives?

TrovaGene's management team includes the following people:

Dr. Thomas H. Adams, CEO & Exec. Chairman (Age 76)
Dr. Mark Erlander, Chief Scientific Officer (Age 59)
Ms. Elizabeth Anderson, VP of Fin. & Admin.
Mr. George Samuel, VP & Gen. Counsel
Ms. Vicki Kelemen, VP of Corp. Communications

What is TrovaGene's stock symbol?

TrovaGene trades on the NASDAQ under the ticker symbol "TROV."

How do I buy shares of TrovaGene?

Shares of TROV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is TrovaGene's stock price today?

One share of TROV stock can currently be purchased for approximately $3.21.

How big of a company is TrovaGene?

TrovaGene has a market capitalization of $35.35 million and generates $250,000.00 in revenue each year. The medical research company earns $-16,410,000.00 in net income (profit) each year or ($2.80) on an earnings per share basis.

What is TrovaGene's official website?

The official website for TrovaGene is www.trovagene.com.

How can I contact TrovaGene?

TrovaGene's mailing address is 11055 FLINTKOTE AVENUE, SAN DIEGO CA, 92121. The medical research company can be reached via phone at 858-952-7570 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff